Peter Kotsonis, PhD
Peter is a PhD-neuroscientist and drug hunter who has worked in both academic and corporate innovation settings. He joined UCSF in 2013, primarily responsible for developing novel business models and, a partnering vision for the campus eco-system that drives towards commercialization.
Peter has experience in pre-IPO academic start-ups (vasopharm GmbH) and larger global organizations (Novartis Ag and Dainippon Sumitomo Pharma Co, Ltd). Whilst at Julius-Maximilians University of Wurzburg (Wurzburg, Germany) he was the project leader and co-inventor of Ronopterin, a novel medicine for traumatic brain injury that is currently in Phase III clinical development and with Orphan Designation. For the resulting work, he and the team were awarded the 2000 Phoenix Pharmacy Ag Pharmazie-Wissenschaftspreis (Munich, Germany). At the Novartis Institute for Medical Science (London, UK) he led a CGRP migraine program. At Sepracor Inc. (MA, USA) he was the head of operations for Discovery and Early Clinical Research, which included aspects of strategy, portfolio management and external innovation. There he also completed the exclusive licensing of a first-in-class antipsychotic, Ulotaront, from a strategic partnership with PsychoGenics Inc. Ulotaront is currently in Phase III clinical development and received FDA Breakthrough designation in 2019.
Peter completed his studies at the University of Melbourne (BSc HONS) and Monash University (PhD). He is the recipient of the prestigious CJ Martin Fellowship from the Australian NH&MRC and, has been a member of the Royal Australian Chemical Institute for over 25 years.